ITabs
Bi-specific antibodies generated from Generoní»s ITabTM platform simultaneously bind to CD3 molecules on human T cells and to specific tumor antigens, forming a synapsis between a tumor cell and T cells linked by the ITabTM antibodies. The formation of a synapsis leads to activation of T cells, and the release of mediators lysing the tumor cells. The ITabTM antibody can drive the expansion of T cells rendering T cells as serial killers of tumor cells.

A-337 is a bi-specific antibody (BsAb) designed to target EpCAM and CD3 (anti-EpCAM, anti-CD3) and is under development for the treatment of patients with solid tumors expressing EpCAM. The epithelial cell adhesion molecule (EpCAM, also known as CD326, 17-A, TACSTD1, EGP40, ESA), was one of the first cancer markers found to be frequently expressed at high levels in human cancers, including colon, ovarian, lung, stomach, pancreas, and prostate cancers. In contrast to conventional anti-cancer therapy approaches, A-337 activates the immune system, specifically T cells in a patient, to kill tumor cells. This new emerging therapeutic approach to treat cancer is called cancer immunotherapy. A Phase I study for A-337 has been initiated in Australia.

A-319 is a bi-specific antibody (BsAb) designed to target CD19 and CD3 (anti-CD19, anti-CD3) and is under development for the treatment of patients with B cell malignancies including ALL, CLL, Lymphoma. A-319 activates the immune system, specifically T cells in a patient, to kill B cells. The China Phase I IND application has been filed with CFDA.